Acasă › Supraponderalitate › Michigan
Studii clinice pentru Supraponderalitate în Michigan
19 studii pentru Supraponderalitate caută participanți în Michigan.
Orașe în Michigan
Text oficial al studiului (în engleză)
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Profound Research, Farmington Hills
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 28 sept. 2026 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Northern Pines Hlth Ctr, PC, Buckley
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07720271A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Great Lakes Research Group, Inc., Bay City
- Great Lakes Research Institute, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Aa Mrc Llc, Flint
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Helen Devos Childrens' Hospital - PIN, Grand Rapids
În curs de recrutareFaza 3
Vârste de la 6 la 17 · Toate sexele · Actualizat 24 sept. 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Great Lakes Research Institute, Southfield
- Revive Research Institute, Inc., Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Farmington Hills
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Revive Research Institute, Inc., Southfield
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07369011A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 22 sept. 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Southfield
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT07743450A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 8 sept. 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- David Fivenson, MD, PLC, Ann Arbor
- The Derm Institute of West Michigan, Caledonia
În curs de recrutareFaza 4
Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Farmington Hills
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Headlands Research - Detroit, Southfield
În curs de recrutareFaza 3
Vârste de la 18 la 99 · Toate sexele · Actualizat 3 sept. 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy
În curs de recrutareFaza 3
Vârste de la 18 la 99 · Toate sexele · Actualizat 27 aug. 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Troy
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT07784725AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Arcturus Healthcare, PLC., Troy
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Ann Arbor
În curs de recrutareFaza 3
Vârste de la 18 la 79 · Toate sexele · Actualizat 10 aug. 2026 · NCT07654361Sursă: ClinicalTrials.gov, date preluate la 3 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.